EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Lipid‐based nanoparticles as drug delivery systems for cancer immunotherapy

Yang Hao, Zhonghao Ji, Hengzong Zhou, Dongrun Wu, Zili Gu, Dongxu Wang, Peter Ten Dijke

MedComm · 2023-08 · 4 (4)

DOI: 10.1002/mco2.339 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 07.08.2023. Verfasst von Yang Hao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Animals College of Animal Sciences Jilin University Changchun China. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 423 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have shown remarkable success in cancer treatment. However, in cancer patients without sufficient antitumor immunity, numerous data indicate that blocking the negative signals elicited by immune checkpoints is ineffective. Drugs that stimulate immune activation‐related pathways are emerging as another route for improving immunotherapy. In addition, the development of nanotechnology presents a promising platform for tissue and cell type‐specific delivery and improved uptake of immunomodulatory agents, ultimately leading to enhanced cancer immunotherapy and reduced side effects. In this review, we summarize and discuss the latest developments in nanoparticles (NPs) for cancer immuno‐oncology therapy with a focus on lipid‐based NPs (lipid‐NPs), including the characteristics and advantages of various types. Using the agonists targeting stimulation of the interferon genes (STING) transmembrane protein as an exemplar, we review the potential of various lipid‐NPs to augment STING agonist therapy. Furthermore, we present recent findings and underlying mechanisms on how STING pathway activation fosters antitumor immunity and regulates the tumor microenvironment and provide a summary of the distinct STING agonists in preclinical studies and clinical trials. Ultimately, we conduct a critical assessment of the obstacles and future directions in the utilization of lipid‐NPs to enhance cancer immunotherapy.

Schlagwörter

Stichwörter der Autor:innen

cancer immunotherapylipid‐based nanoparticlesstimulator of interferon genestumor microenvironmenttype I interferon

Autor:innen und Institutionen

  • Department of Laboratory Animals College of Animal Sciences Jilin University Changchun China.
  • Department of Basic Medicine Changzhi Medical College Changzhi China.
  • Department of Cell and Chemical Biology and Oncode Institute Leiden University Medical Center Leiden The Netherlands.
  • Departure of Philosophy, Faculty of Humanities Leiden University Leiden The Netherlands.
  • Department of Radiology Leiden University Medical Center Leiden The Netherlands.

Förderung

  • China Postdoctoral Science Foundation

Zitieren

APA

Hao, Y., Ji, Z., Zhou, H., Wu, D., Gu, Z., Wang, D., & Ten Dijke, P. (2023). Lipid‐based nanoparticles as drug delivery systems for cancer immunotherapy. MedComm, 4(4). https://doi.org/10.1002/mco2.339

Vancouver

Hao Y, Ji Z, Zhou H, Wu D, Gu Z, Wang D, et al. Lipid‐based nanoparticles as drug delivery systems for cancer immunotherapy. MedComm. 2023;4(4). doi:10.1002/mco2.339

BibTeX
@article{Hao2023,
  author = {Hao, Yang and Ji, Zhonghao and Zhou, Hengzong and Wu, Dongrun and Gu, Zili and Wang, Dongxu and Ten Dijke, Peter},
  title = {Lipid‐based nanoparticles as drug delivery systems for cancer immunotherapy},
  journal = {MedComm},
  year = {2023},
  volume = {4},
  number = {4},
  doi = {10.1002/mco2.339}
}
Kostenlos starten →